190 related articles for article (PubMed ID: 34272252)
1. Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.
Golding B; Lee Y; Golding H; Khurana S
Ann Rheum Dis; 2021 Oct; 80(10):1359-1361. PubMed ID: 34272252
[No Abstract] [Full Text] [Related]
2. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
Albach FN; Burmester GR; Biesen R
Ann Rheum Dis; 2021 Oct; 80(10):1361-1362. PubMed ID: 34167947
[No Abstract] [Full Text] [Related]
3. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
[No Abstract] [Full Text] [Related]
4. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
[No Abstract] [Full Text] [Related]
5. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
Prendecki M; Clarke C; Edwards H; McIntyre S; Mortimer P; Gleeson S; Martin P; Thomson T; Randell P; Shah A; Singanayagam A; Lightstone L; Cox A; Kelleher P; Willicombe M; McAdoo SP
Ann Rheum Dis; 2021 Oct; 80(10):1322-1329. PubMed ID: 34362747
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
Geisen UM; Berner DK; Tran F; Sümbül M; Vullriede L; Ciripoi M; Reid HM; Schaffarzyk A; Longardt AC; Franzenburg J; Hoff P; Schirmer JH; Zeuner R; Friedrichs A; Steinbach A; Knies C; Markewitz RD; Morrison PJ; Gerdes S; Schreiber S; Hoyer BF
Ann Rheum Dis; 2021 Oct; 80(10):1306-1311. PubMed ID: 33762264
[TBL] [Abstract][Full Text] [Related]
8. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
Spiera R; Jinich S; Jannat-Khah D
Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
[No Abstract] [Full Text] [Related]
9. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
Terpos E; Trougakos IP; Gavriatopoulou M; Papassotiriou I; Sklirou AD; Ntanasis-Stathopoulos I; Papanagnou ED; Fotiou D; Kastritis E; Dimopoulos MA
Blood; 2021 Jul; 137(26):3674-3676. PubMed ID: 33861315
[No Abstract] [Full Text] [Related]
10. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.
Ruddy JA; Connolly CM; Boyarsky BJ; Werbel WA; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
Ann Rheum Dis; 2021 Oct; 80(10):1351-1352. PubMed ID: 34031032
[No Abstract] [Full Text] [Related]
11. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
[TBL] [Abstract][Full Text] [Related]
12. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
Braun-Moscovici Y; Kaplan M; Braun M; Markovits D; Giryes S; Toledano K; Tavor Y; Dolnikov K; Balbir-Gurman A
Ann Rheum Dis; 2021 Oct; 80(10):1317-1321. PubMed ID: 34144967
[TBL] [Abstract][Full Text] [Related]
13. Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies.
Hod T; Ben-David A; Olmer L; Levy I; Ghinea R; Mor E; Lustig Y; Rahav G
Transplantation; 2021 Nov; 105(11):e234-e243. PubMed ID: 34310101
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
Simon D; Tascilar K; Fagni F; Krönke G; Kleyer A; Meder C; Atreya R; Leppkes M; Kremer AE; Ramming A; Pachowsky ML; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Berking C; Sticherling M; Neurath MF; Schett G
Ann Rheum Dis; 2021 Oct; 80(10):1312-1316. PubMed ID: 33958324
[TBL] [Abstract][Full Text] [Related]
15. Can immune responses predict which vaccines work best?
Cohen J
Science; 2021 Jul; 373(6551):142-143. PubMed ID: 34244387
[No Abstract] [Full Text] [Related]
16. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
17. CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients.
Schulz E; Hodl I; Forstner P; Hatzl S; Sareban N; Moritz M; Fessler J; Dreo B; Uhl B; Url C; Grisold AJ; Khalil M; Kleinhappl B; Enzinger C; Stradner MH; Greinix HT; Schlenke P; Steinmetz I
Front Immunol; 2021; 12():803742. PubMed ID: 34950155
[TBL] [Abstract][Full Text] [Related]
18. The long road.
Cohen J
Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
[No Abstract] [Full Text] [Related]
19. SARS-CoV-2 Variant Antibodies Wane 6 Months After Vaccination.
Abbasi J
JAMA; 2021 Sep; 326(10):901. PubMed ID: 34519816
[No Abstract] [Full Text] [Related]
20. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]